Ação antimicrobiana e antibiofilme do extrato de Quillaja saponaria sobre cepas clínicas multirresistentes de Pseudomonas aeruginosa
Carregando...
Data
2022-07-04
Autores
Silva, Allanis Mota da
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
Objetivo: avaliar in vitro a atividade antimicrobiana e antibiofilme do extrato glicólico
de Quillaja saponária (quilaia) sobre três cepas clínicas multirresistentes (P1, P2, P3)
e uma cepa padrão (ATCC 15442) de Pseudomonas aeruginosa. Material e Métodos:
A determinação da Concentração Inibitória Mínima (CIM) foi realizada pela técnica de
microdiluição em caldo, de acordo com a CLSI (norma M7–A9) e a Concentração
Microbicida Mínima (CMM) foi determinada por alíquotas semeadas dos poços em
ágar Brain Heart Infusion - BHI (Himédia). Testes em biofilmes foram realizados,
sendo o extrato de quilaia aplicado nas concentrações pré-determinadas pela CMM.
A viabilidade dos biofilmes foi mensurada pelo teste de MTT e a quantificação de
biomassa pelo cristal violeta. Os dados foram analisados pelo método ANOVA
complementado pelo Teste de Tukey (p≤0,05). Resultados: O extrato quilaia
apresentou CIM e CMM no valor de 3,1 mg/mL frente às cepas clínicas P1 e P3, e 1,5
mg/mL para a cepa clínica P2 e ATCC 15442, portanto, foi considerado bactericida
contra as cepas avaliadas. O maior percentual de redução de biomassa em
tratamentos de 5 min e 24 h foram, respectivamente, 37,6% (cepa P2) e 50,1% (cepa
P3) quando comparado ao grupo controle. Em relação à redução da viabilidade, em
testes de 5 min e 24 h de contato com o extrato, os valores máximos obtidos foram,
respectivamente, 51,5% (cepa P2) e 49% (cepa P1), diferindo estatisticamente do
grupo controle. Conclusão: O extrato glicólico de quilaia possui ação bactericida e
antibiofilme frente às cepas multirresistentes de Pseudomonas aeruginosa.
Objective: To evaluate in vitro the antimicrobial and antibiofilm activity of Quillaja saponaria (quillaia) glycolic extract against three multidrug-resistant clinical strains (P1, P2, P3) and a standard strain (ATCC 1542) of Pseudomonas aeruginosa. Material and Methods: The Determination of the Minimum Inhibitory Concentration (MIC) was performed by the broth microdilution technique, according to CLSI (M7–A9 standard) and the Minimum Microbicidal Concentration (MMC) was determined by seeded aliquots from the wells in agar Brain Heart Infusion - BHI (Hymedia). Bio tests were carried out, and the quilaia extract was applied in pre-determined packages by CMM. The viability of biofilms was measured by the MTT test and quantification of violet biomass. Data were analyzed by the ANOVA method complemented by the Tukey method (p≤0.05). Results: The quillaia extract presented CIM and CMM in the amount of 3.1 mg/mL against the clinical strains P1 and P3, and 1.5 mg/mL for the bactericidal strain P2 and ATCC 15442, therefore, it was considered against like strains. The highest percentage of biomass reduction in treatments of 5 min and 24h were, respectively, 37.6% (P2 strain) and 50.1% (P3 strain). Regarding the reduction of viability, in tests of 5 min and 24 h of contact with the maximum, the values obtained were, respectively, 51.5% (strain P2) and 49% (strain P1). Conclusion: The quillaia glycolic extract has antimicrobial and antibiofilm action against multidrug-resistant strains of Pseudomonas aeruginosa.
Objective: To evaluate in vitro the antimicrobial and antibiofilm activity of Quillaja saponaria (quillaia) glycolic extract against three multidrug-resistant clinical strains (P1, P2, P3) and a standard strain (ATCC 1542) of Pseudomonas aeruginosa. Material and Methods: The Determination of the Minimum Inhibitory Concentration (MIC) was performed by the broth microdilution technique, according to CLSI (M7–A9 standard) and the Minimum Microbicidal Concentration (MMC) was determined by seeded aliquots from the wells in agar Brain Heart Infusion - BHI (Hymedia). Bio tests were carried out, and the quilaia extract was applied in pre-determined packages by CMM. The viability of biofilms was measured by the MTT test and quantification of violet biomass. Data were analyzed by the ANOVA method complemented by the Tukey method (p≤0.05). Results: The quillaia extract presented CIM and CMM in the amount of 3.1 mg/mL against the clinical strains P1 and P3, and 1.5 mg/mL for the bactericidal strain P2 and ATCC 15442, therefore, it was considered against like strains. The highest percentage of biomass reduction in treatments of 5 min and 24h were, respectively, 37.6% (P2 strain) and 50.1% (P3 strain). Regarding the reduction of viability, in tests of 5 min and 24 h of contact with the maximum, the values obtained were, respectively, 51.5% (strain P2) and 49% (strain P1). Conclusion: The quillaia glycolic extract has antimicrobial and antibiofilm action against multidrug-resistant strains of Pseudomonas aeruginosa.
Descrição
Palavras-chave
Pseudomonas aeruginosa, Quillaja saponaria, Ação antimicrobiana, Biofilme, Antimicrobial action, Biofilm